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Abstract 
Ventricular dysfunction is a state where an adequate cardiac output cannot be 
maintained even with support of compensatory mechanisms. Left sided dysfunction gives rise 
to inadequate systemic circulation and congestion of the lungs manifesting as tachycardia, 
muffled heart sound, gallop rhythm, tachypnea, cough, breathlessness & enlargement of the 
heart and ultimately leads to cardiac failure. Present study comprehends the selection of 
patients with left ventricular dysfunction (LVD) and trial of an Ayurvedic formulation coded 
as Cardi-16 for its efficacy to combat the disorder in comparison with Digitalis lanata Ehrh. 
A total of 24 patients of LVD were selected for the study who were randomly divided into 
three groups with one group being treated with Cardi-16, second with Digitalis lanata Ehrh. 
and third with combined therapy. 20 patients (8 in group I, 6 in group II and 6 in Group III) 
completed the course of treatment. Left ventricular ejection fraction (LVEF) was measured to 
assess the effect of therapy. The effect of treatment on chief complaints and symptoms was 
also evaluated. Both the treatments were found effective in relieving symptoms and 
increasing ejection fraction but the results were more pronounced in the groups in which 
Cardi 16 was given.  
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Introduction  
Heart failure, the most common 
and important precursor of which is left 
ventricular systolic dysfunction, is a 
common cardiovascular condition with 
rising incidence and prevalence (1). It 
leads to high mortality and major 
impairment of quality of life (2-4). It is 
also a leading cause of healthcare 
expenditure through repeated 
hospitalization and high treatment costs 
(5). About 28% of all deaths in India are 
caused by cardiovascular diseases (6). 
Cardiovascular disorders account for 
roughly 40 million deaths annually (7).  
Despite important advancements in 
the pharmacotherapy of heart failure, the 
actual percent reduction in mortality 
associated with the use of these agents has 
been relatively unpretentious. Moreover 
the available pharmacological agents are 
also not free from various side effects (8). 
Hence there is immense requirement of 
certain drugs which can increase cardiac 
efficiency and can increase the 
*Corresponding Author: 
Alka (Babbar) Kapoor  
C-466, Sarita vihar,  
New Delhi-110076 
Ph. No: +91-9312330249 
E-mail: dralkakapoor@gmail.com 
Published online in http://ijam.co.in 
  ISSN: 0976-5921 
Babbar Kapoor et.al., Evaluation of Indigenous drug in Left Ventricular Dysfunction 
 
192 
performance of compromised heart for 
healthy living in a natural way with least 
possible side effects. Present work is an 
attempt in this direction 
To treat left ventricular dysfunction 
(LVD) on Ayurvedic principles, it is 
necessary to identify the nature of the 
disease in terms of its component dosha 
(humor), dushya (part which is affected) 
and adhishthana (abode). In LVD, 
impairment of the cardiac function is 
brought about by derangement of tridoshas 
(three humors vata, pitta & kapha) with 
predominance of vata and kapha. As heart 
is the root of rasavaha srotas and is the 
sole organ responsible for rasa-samvahan 
(circulation), vitiation of rasa-vaha srotas 
and rasa dhatu by morbid doshas leads to 
heart disease (9).  
The etiological factors which lead 
to vitiation of this srotas include foods 
which are guru (not easily digestible), 
atisheeta (cold), atisnigdha (oily) 
psychological factors like chinta (worries) 
etc.(10).When an individual is indisposed 
through above mentioned aetiological 
factors; the disease process ensues in the 
form of tridoshic arrhythmia and vitiation 
of doshas predominantly ‘kapha’ in this 
case. This vitiated kapha owing to its 
sheeta, guru and manda gunas leads to 
weakening of koshthagni (digestive fire) 
and its moiety rasagni. When agni 
becomes weak, the food does not get the 
required digestion leading to accumulation 
of a number of unwanted by-products of 
digestion and metabolism called ama. The 
presence of ama renders the body 
metabolically slow and sluggish along 
with varying degrees of blockage of 
channels of the body at different levels 
from gross to molecular level. During its 
sojourn in these channels, it tends to 
adhere to the walls thereby narrowing the 
passages or causing obstruction, termed as 
srotorodha.  Increased impermeability and 
sluggishness of the body channels or the 
rasavahi srotases offer increased resistance 
and compel the heart to pump blood more 
vigorously at a rate commensurate with the 
metabolic requirements of the body. In 
presence of this hemodynamic burden or 
increased workload, the cardiac muscles 
get hypertrophied as a compensatory 
mechanism to maintain the overall 
performance. However, if this ama state 
and excessive hemodynamic burden 
persists, the heart ultimately fails to 
perform its function. Secondly if morbid 
kapha and ama block the channels 
supplying nutrition to the heart (e.g. 
coronary arteries) then such obstruction 
leads to deficiency of nutrition and cardiac 
metabolism is hampered which in turn 
affects its performance. It is essential to 
break this pathogenesis to get the desired 
results. Thus treatment of LVD aims at i) 
enhancement of digestive fire and 
balancing vitiated doshas i) reduction of 
cardiac workload-both preload and after-
load; ii) control of excessive salt and water 
retention, iii) enhancement of myocardial 
contractility and vascular elasticity. 
Selection of ingredients was done keeping 
these objectives in mind. 
 
Aims and objectives 
Present work was undertaken with 
the objective to clinically evaluate an 
Indigenous compound drug coded as 
Cardi-16 in heart disease (hridroga) with 
special reference to left ventricular 
dysfunction on various scientific 
parameters. 
 
Materials and Methods 
Selection of the Patients  
Patients were selected from the 
outpatient and inpatient department of 
Kayachikitsa of ‘A’ class Govt. Ayurvedic 
Hospital, Motichauhatta and R.V.P.S.S 
Ayurvedic Hospital, under M.M.M., Govt. 
Ayurvedic College, Udaipur. A total of 24 
patients of LVD, above 18 years, of either 
sex, satisfying the inclusion criteria were 
finally enrolled in the study after thorough 
baseline screening. Informed consent was 
taken from the patient before including 
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them in the trial. They were randomised 
into three groups using permuted block 
randomization technique. During the 
study, 04 patients dropped out and only 20 
were followed till the end (8 in group 1, 6 
each in group 2 & 3) 
 
Diagnostic Criteria 
The patients were subjected to 
echocardiography to evaluate ejection 
fraction (EF) to confirm the diagnosis of 
LVD. The patients having less than normal 
EF values (i.e. 67+8%) were taken into 
consideration. 
 
Inclusion Criteria 
Following group of patients were 
taken into consideration for the present 
clinical study. 
(i) Patients between18- 80 years of age of 
either sex with EF< 59%  
(ii) Patients with associated: - 
Stable, chronic cases of Ischemic heart 
disease (IHD), Cardiomyopathy, 
Hypertension (HT), Controlled type 2 
diabetic patients without complications 
and not on insulin, Patients willing to 
give consent to participate in the study. 
 
Exclusion Criteria 
Following group of patients was 
not taken intos consideration for the 
present clinical study. 
(i) Patients above 80 years of age 
(ii) Patients unwilling to participate 
(iii)Patients with following associated 
disorders- 
Cardiac: Acute myocardial infarction 
(Newly diagnosed acute cases), severe 
valvular defects, congenital heart 
disease, pericarditis, arrhythmia, 
patients already on digoxin therapy.  
Extra Cardiac: Renal failure, Type I 
diabetic patients, uncontrolled Type 2 
diabetic patients with complications, 
chronic alcoholics, pregnant/lactating 
women,  
 
Criteria for Early Withdrawal of 
Subjects 
Failure of subjects to adhere to 
protocol requirements, subject consent 
withdrawal, disease progression and 
subject gets pregnant (in case of female 
patients)  
 
Drugs Used  
An Ayurvedic compound coded as 
Cardi – 16 
 
A total of following 16 drugs were 
selected for this compound  
S. 
No. 
Name of 
the 
Ingredient 
Latin 
Name 
Part 
Used 
Propo
rtion 
1.  Arjuna Termina
lia 
arjuna 
Roxb. 
W. & 
A.   
bark 
extract 
6 parts 
2.  Gokshura Tribulus 
terrestri
s Linn. 
fruit 
extract 
7 parts 
3.  Gulab Rosa 
centifoli
a Linn. 
flower 
extract 
6 parts 
4.  Punarnava Boerrha
via 
diffusa 
Linn. 
whole 
plant 
extract 
3 parts 
5.  Pushkarmo
ola 
Inula 
racemos
a 
Hook.f. 
root 
extract 
8 parts 
6.  Tamboola Piper 
betle 
Linn. 
leaf 
extract 
½ part 
7.  Karpura Cinnam
omum 
campho
ra Nees 
& 
Eberm 
extract 3 parts 
8.  Brihad Ela Amomu
m 
subulatu
m Roxb. 
Seeds 
powder 
8 parts 
9.  Van 
Palandu 
Urginea 
indica 
bulb 
extract 
½ part 
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Kunth 
10.  Ankola Alangiu
m 
salvifoli
um 
(Linn.f.)
; Wang 
root 
ghan-
satwa 
8 parts 
11.  Pita 
karveera 
Thevetia 
neriifole
a Juss. 
root 
ghan -
satwa 
1 part 
12.  Erandakark
ati 
Carica 
papaya 
Linn. 
leaves’ 
juice. 
8 parts 
13.  Abhraka  Mica bhasma 12 
parts 
14.  Jaharmohra  Serpenti
ne 
pishti 6parts 
15.  Shuddha 
Shilajita 
Bitumen extract 25 
parts 
16.  Mriga 
Shringa  
Hart’s 
horn 
bhasma 6 parts 
 
Ingredients no.1-9 were procured 
in dry powder form. The Ghan satwa of 
ingredient no. 10 & 11 were formed in 
water after proper purification, as per the 
process laid down in Ayurvedic texts(11)
.
. 
Both these ghan satwa taken together were 
impregnated in juice of ingredient no.12. 
This mixture was then allowed to dry in 
shade and triturated carefully to get a fine 
powder. The requisite processing of 
ingredients 13-16 was done as per the 
process laid down in Ayurvedic texts (12). 
Finally all the ingredients were mixed in a 
pulveriser. The proportion of each 
ingredient was fixed on the basis of 
potency of the drug according to principles 
of Dravya guna and Bhaishajya kalpana.  
Capsules were prepared, each containing 
500mg of the prepared compound.  
Dosage: 2 capsules three times a day after 
meals with water i.e., after breakfast, lunch 
and dinner.  
 
II. Hritpatri (Digitalis lanata Ehrh.) 
Capsules 
Hritpatri (Digitalis lanata Ehrh.) 
leaves were made into fine powder and 
filled into gelatine capsules each 
containing 100 mg of the prepared 
Hritpatri powder 
Dosage: 1 capsule BD after meals with 
water i.e., after breakfast and dinner 
The dose of Hritpatri was decided 
according to its leaf powder doses given in 
texts of pharmacology (13).
 
 
Administration of Drug 
(i)  Group I      - This group 
comprising of 8 patients, was given 
Cardi-16 capsules in the dose of 3gm 
per day with luke warm water for 2 
months. 
(ii) Group II   - This group was 
given Hritpatri capsules with luke 
warm water for 2 months. 6 patients 
were included in this group. 
(iii) Group III - This group 
comprised of 6 patients. Both Cardi-16 
and Hritpatri capsules were given to 
the patients of this group. 
The OPD patients were advised to 
follow-up initially after a week and then at 
interval of 15 days. At every visit patients 
were assessed for their symptoms, pulse, 
blood pressure, respiratory rate, weight 
etc. 
 
Criteria of Assessment 
The efficacy of the therapy was 
assessed on the basis of subjective as well 
as objective criteria. 
 
Subjective Criteria: 
All the patients registered for the 
trial were looked into for any changes in 
their clinical manifestations and growing 
feeling of well being if any, after the 
therapy. Following symptoms were taken 
into consideration. 
1)  Breathlessness (Shwasa)   
2)  Fatigability (Klama)    
3)  Chest pain (Uro-ruja  
4)  Palpitation (Hritkampa) 
Above clinical symptoms were put under 
functional class according to the criteria 
laid down by New York Heart Association 
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(1964), and were assessed according to the 
grades- 
Grade I      -  No limitation of physical 
activity. No symptoms with ordinary 
exertion 
Grade  II     -   Slight limitation of 
physical activity. Ordinary activity causes 
symptoms 
Grade III   -  Marked limitation of 
physical activity. Less than ordinary 
activity causes    symptoms, asymptomatic 
at rest. 
Grade IV   - Inability to carry out any 
physical activity without discomfort. 
Symptoms at rest. 
The assessment was done before 
starting the treatment and after 60 days of 
treatment. Improvement and effect of drug 
was assessed on the basis of relief in 
number of symptoms. 
Relief in 75% or more 
symptoms   
- Excellent 
Relief in 50-74.9% or 
more symptoms 
- Good 
Relief in 25-49.9% or 
more symptoms 
- Average 
Relief in less than 25% 
symptoms  
 
- 
Below 
average 
 
Objective criteria 
Evaluation of Ejection Fraction 
(EF) by echocardiography before and after 
treatment was done & any change in EF 
percentage was recorded.  
Exercise Tolerance in patients 
measured by calculating the difference in 
post exertion values of Pulse, B.P. and 
Respiratory rate. At every visit, patients 
were subjected to a piece of exercise- 
climbing a set of 50 stairs and about 50 
meters brisk walk on plain surface. After 
exertion any change in the vitals was 
recorded. Result was evaluated from the 
premedication & post medication 
difference in values of vitals. 
 
 
Observations and Results 
In this study, all the patients selected were in the age group of 18-80 years. However, 
majority of the patients were between 35 to 50 years of age (55%). Prevalence of this disease 
was found more in educated (60%) & service class (60%) patients. Almost all the patients 
registered were addicted either to smoking (60%) or chewing tobacco (40%) or alcohol etc. 
Most of the patients registered were having kaphaj (40%) or vata-kaphaj (45%) deha prakriti 
and madhyama satwa (60%). 35% patients of the registered LVD cases were known cases of 
ischemic heart disease while 20% were suffering from hypertension. Table 1 exhibits 
distribution of patients according to different characteristics. 
 
Table 1: Distribution of patients according to different characteristics 
Characteristic No. of patients Percentage 
Age group 
35-50 11 55 
50-65 06 30 
65-80 03 15 
Sex 
Male 11 55 
Female 09 45 
Educational status 
Educated 12 60 
Illiterate 08 40 
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Work profile 
Service class 12 60 
Business Class 08 40 
House Wife 07 35 
Labour Class 03 15 
Diet 
Vegetarian 12 60 
Non Vegetarian 08 40 
Addiction 
Tobacco Chewing 12 60 
Smoking 08 40 
Alcohol intake 07 35 
Both smoking and drinking 03 15 
Others 06 30 
Economic status 
Lower & lower middle class (< 5000pm ) 05 25 
Middle class (5000-15000pm ) 06 30 
Higher income group (> 15000pm) 09 45 
Prakriti 
Vataj 02 10 
Pittaja 01 05 
Kaphaja 08 40 
Vat-Pittaja 00 0 
Vat Kaphaja 09 45 
Pitta Kaphaja 00 00 
Sannipattaja 00 00 
Satwa 
Awara 07 35 
Madhyama 12 60 
Prawara 01 05 
Associated disorder 
IHD 07 35 
HT 04 20 
DM 03 15 
Obesity 02 10 
Cor Pulmonale 01 05 
RHD 01 05 
PSVT 01 05 
Depression 01 05 
 
Effects of Cardi 16 (group I), Hritpatri (group II) and combined therapy (group III) on 
clinical recovery of symptoms of LVD are shown in Table 2, 3 &4 respectively.  Effect of 
therapy on exercise tolerance and left ventricular ejection fraction in group I, II and III are 
represented in Table No. 5-10. 
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Table 2: Clinical recovery of Symptoms of LVD in Group I 
Observations Mean S.D. S.E. t p 
 B.T. A.T. Diff.  +   
Breathlessness 3.12 1.87 1.25 0.46 0.16 7.64 <0.0001              
Fatigability  2.75 1.75 1.00 0.53 0.19 5.29 <0.001                 
Chest pain 2.37 1.37 1.00 0.93 0.33 3.05 <0.02            
Palpitation 2.5 1.37 1.12 1.126 0.39 2.83 <0.03           
 
 
Table 3: Clinical recovery of symptoms of LVD in Group II 
Observations Mean S.D. S.E. t p 
 B.T. A.T. Diff.  +   
Breathlessness 2.67 1.50 1.17 0.41 0.17 7 <0.001 
Fatigability  3.17 1.50 1.67 0.52 0.21 7.91 <0.001                 
Chest pain 2.50 2.00 0.50 0.55 0.22 2.24 <0.1                        
Palpitation 3.17 2.00 1.17 0.41 0.17 7 <0.001 
 
 
Table 4: Clinical recovery of symptoms of LVD in Group III 
Observations Mean S.D. S.E. t p 
 B.T. A.T. Diff.  +   
Breathlessness 3.17 1.5 1.67 0.52 0.21 7.91 <0.001 
Fatigability  3.33 1.67 1.67 0.52 0.21 7.91 <0.001 
Chest pain 2.33 1.17 1.17 0.75 0.30 3.80 <0.01 
Palpitation 2.67 1.33 1.33 1.21 0.49 2.70 <0.05 
 
 
Table 5: Exercise tolerance in Group I - difference in post exertion values of pulse, B.P. 
and respiratory rate. 
Observations Mean S.D. S.E. t p 
 B.T. A.T. Diff.  +   
Pulse rate 25.75 13.25 12.5 3.817 1.35 9.26 <0.0001                  
Respiratory rate 6.38 3.13 3.25 1.28 0.45 7.17 <0.001                   
Systolic B. P. 16.5 6.63 9.87 7.94 2.81 3.52 <0.01                
Diastolic B.P. 6 3.5 2.5 5.40 1.91 1.31 >0.2 
 
 
Table 6:  Exercise tolerance in Group II- difference in post exertional values of pulse, 
B.P. and respiratory rate. 
Observations Mean S.D. S.E. t p 
 B.T. A.T. Diff.  +   
Pulse rate 27.83 15.33 12.5 21.59 8.82 1.42 >0.2 
Respiratory 
rate 7.33 4 3.33 1.63 0.67 5.00 <0.01                 
Systolic B. P. 14.5 8.33 6.17 5.46 2.23 2.77 <0.05                     
Diastolic B.P. 5.67 2 3.67 3.44 1.41 2.61 <0.05                    
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Table 7: Exercise tolerance in Group III- difference in post exertional values of pulse, 
B.P. and respiratory rate. 
Observations Mean S.D. S.E. t p 
 B.T. A.T. Diff.  +   
Pulse rate 28.83 16.33 12.5 4.64 1.89 6.60 <0.001                  
Respiratory rate 6.17 2.83 3.33 1.63 0.67 5.00 <0.005               
Systolic B. P. 9.33 7.67 1.67 6.12 2.50 0.67 >0.5 
Diastolic B.P. 5.17 4.67 0.5 5.92 2.42 0.21 >0.5 
 
Table 8: Changes in ejection fraction value in Group I 
Observations Mean S.D. S.E. t p 
 B.T. A.T. Diff.  +   
Ejection 
fraction 49.17 60.33 11.17 6.047 2.47 4.523 <0.01           
 
Table 9: Changes in ejection fraction value in Group II 
Observations Mean S.D. S.E. t p 
 B.T. A.T. Diff.  +   
Ejection 
fraction 47.33 48.83 1.5 1.05 0.43 3.503 <0.02    
 
Table 10: Changes in ejection fraction value in Group III 
Observations Mean S.D. S.E. t p 
 B.T. A.T. Diff.  +   
Ejection 
fraction 
46.83 54.83 8 2.83 1.15 6.93 
<0.001 
 
 
Table 11: Symptomatic relief 
11a. Group I 
S.No. Category of results No. of patients % of results 
1. Excellent 5 62.50 
2. Good 2 25.00 
3. Average 1 12.50 
4. Below Average - - 
 Total 8  
 
11b. Group II 
S.No. Category of results No. of patients % of results 
1. Excellent - - 
2. Good 4 66.60 
3. Average 2 33.33 
4. Below Average 0 - 
 Total 6  
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11c. Group III 
S.No. Category of results No. of patients % of results 
1. Excellent  - - 
2. Good 6 100.00 
3. Average - - 
4. Below Average - - 
 Total 6  
On comparing the results, it was observed that the effect of Cardi 16 was better in 
relieving symptoms of breathlessness (p<0.0001),  chest pain (p<0.02) and fatigability 
(p<0.001). However Hritpatri worked better for palpitation (p<0.001). [Table 2], [Table 
3], [Table 4] . 
Exercise tolerance was also found better in the group treated with Cardi-16 [Table 
5], [Table 6], [Table 7]. 
On comparing the effects of therapies on Ejection fraction, it was seen that the results 
were better in the group in which Cardi -16 was given [Table 12] 
 
Table 12:  Comparative improvement of different criterion of Hridroga (LVD) in three 
groups of patients. 
Observations I group II group III group 
Symptomatic 
improvement 
t=4.70              
p<0.015 
t=5.15                           
p<0.02 
t=4.66                         
p<0.015 
Improvement in 
exercise tolerance 
t=5.32                  
p<0.1 
t=2.95                               
p<0.1 
t=3.12                             
p<0.5 
Improvement in 
ejection fraction 
t=4.22               
p<0.01 
t=3.50                            
p < 0.02 
t=6.92                        
p<0.001 
 
 
Fig. 1: Symptomatic relief in three groups 
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Fig.2: Extent of symptomatic relief in three groups 
 
 
 
 
Fig.3: Improvement of Ejection Fraction value in three groups 
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Fig. 4: Comparative improvement of ejection fraction value in three groups 
 
 
 
Discussion  
The review of Ayurvedic literature 
indicates that Hridroga is described in 
most Ayurvedic texts in very brief. On the 
other hand modern description of 
cardiovascular disorders is very extensive. 
Various types of cardiac disorders have 
been described. Out of these cardiac 
failure is most troublesome to treat and left 
ventricular dysfunction is the prodromal 
stage of cardiac failure. In LVD, 
impairment of cardiac function is brought 
about by derangement of tridoshas with 
predominance of vata and kapha dosha, 
agnimandya (weak digestive fire) and 
srotosang (obstruction in body channels). 
The ingredients of proposed drug were 
selected to break down this pathogenesis 
and normalize the function of heart by 
restoring the balance of vata, pitta & 
kapha. 
While selecting the patients, it was 
observed that most of the patients were in 
the age group of 35-50 years. Previous 
studies have shown that this problem is 
common in old age group (14). However 
due to increasing stress and lifestyle 
changes, cardiac problems are increasing 
in middle and younger age group also. 
Probably due to same reason, the 
prevalence of this disease was found more 
in middle class, educated, competent 
patients who are always sustained to 
mental stress so as in service class and 
house wives. Dietary habits and addictions 
also play a pivotal role in the prevalence of 
this disease. Almost all the patients 
registered were addicted either to smoking 
or chewing tobacco or alcohol etc. Several 
previous studies also reveal that drinking 
alcohol and smoking or chewing tobacco 
is predisposing factor for the cardiac 
diseases (15).
  
The patients were also subjected to 
prakriti (psychosomatic constitution) and 
satwa (psychological qualities) 
examination. Majority of the patients were 
found to have ‘kaphaj’ or ‘vata-kaphaj’ 
type of constitution and madhyam or 
‘awar’ satwa. This can be explained as the 
disease is sannipataja with predominance 
of kapha and vata, hence the person with 
same prakritik doshas are more prone, to 
get the disease. Madhyam and awara 
Satwa patients are comparatively 
emotionally unstable personalities with a 
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low level of mental stamina and hence are 
easily afflicted by psychosomatic 
disorders. 
The most important symptoms 
which the patients presented with were 
breathlessness on exertion, chest pain, 
fatigability and palpitation. Syncopal 
attacks, cough with expectoration, edema 
of dependent parts, gastro intestinal 
disturbances were among other important 
symptoms. 
It was observed that there was 
significant improvement in clinical 
features of LVD like breathlessness, chest 
pain, and fatigability after the therapy in 
Group I & III, in which Cardi-16 was 
administered. [Table 2, 3 & 4]. Patients 
subjected to the treatment with Cardi -16 
also reported increase in their urine output. 
Reduction in diastolic blood pressure was 
also observed in patients with mild 
hypertension. Probably this way the drug 
has facilitated reduction in after load and 
improvement in diastolic function. Drug 
has also exhibited positive inotropic 
activity. Significant improvement in EF 
value was observed in group I (p<0.01) 
and group III (p<0.001) [Table 8, 10]. II 
group patients also reported improvement 
in clinical features and slight increase in 
EF (p<0.2) [Table 9] but the percentage of 
benefit was less as compared to Group I. 
Some patients of Group II developed 
nausea and anorexia. Cardi-16 was well 
tolerated by all the patients. No side 
effects or toxic effects were reported by 
any patients. 
Most of the drugs in cardi-16 have 
laghu (light), ruksha (non unctuous) 
tikshna (sharp) gunas (properties), katu 
vipaka and ushna veerya (hot potency). 
These properties make cardi-16 igneous in 
nature, kapha vata shamak and jathragni 
stimulant. This stimulation of jathragni 
indirectly stimulates rasagni and helps in 
digestion and removal of ama from the 
srotases and thus helps in arresting the 
etiopathogenesis. 
Moreover owing to the properties 
of ingredients of cardi-16, it has probably 
worked as ‘rasayan’, ‘diuretic’ ‘hridya’, 
‘ampachak’ as well as antioxidant. 
Shilajeet and abhrak bhasma have 
rasayana properties, so they may create an 
improved nutritional status by acting on 
the level of rasa, agni, and srotas. 
Jaharmohra pishti, arjuna, tamboola, 
gulab work by their ‘hridya prabhava’ 
having elective affinity for heart and 
circulatory system. Punarnava is a potent 
diuretic and shringa bhasma, pushkarmool 
& ela are specially honored for their pain 
alleviating properties (16, 17). Ingredients 
like arjuna, ela, betel leaves, erand karkati 
have definite antioxidant, phenolic and 
flavonoid content which can scavenge free 
radicals by one way or the other and lower 
the risk of heart disease. 
From the modern concept, the drug 
should have positive inotropic and diuretic 
action and should be able to optimize both 
preload and after load by vasodilatory 
action. Cardi-16 seems to perform all the 
three functions to some extent and 
supposed to have anti-oxidant and 
preventive action as well. Observations on 
parameters like Ejection fraction, Blood 
pressure, heart rate, respiratory rate, and 
clinical well being prove that medicine 
surely is a potent cardio tonic. However it 
is a matter of further research that what the 
drug did to the myocardial cells—
increased their nutritional status 
regenerated dead cells or increased vigor 
of resting cells. 
 
Conclusion 
LVD is an alarming syndrome 
which ultimately leads to a serious disease 
heart failure, having chronic 
etiopathogenesis requiring long term 
therapy. This study reveals that Cardi-16 
has strong cardio tonic, inotropic and 
cardio protective properties which help in 
improvement of LVEF. It also has potent 
diuretic effect that helps in reducing the 
after load and improves diastolic function. 
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Hence it can be used effectively in the 
management of LV dysfunction to slow 
down the progress of the disease in 
prevention of heart failure. This study was 
done on small sample. Studies with larger 
samples and long term follow up should be 
done to confirm our findings. 
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